Tezepelumab, an anti-TSLP monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial

•Thymic stromal lymphopoietin may initiate inflammation and therefore be a key target for atopic dermatitis treatmentHere, thymic stromal lymphopoietin blockade shows limited efficacy after 12 weeks' treatment; findings at later time points suggest that future clinical trials may require longer treatment periods to determine a significant treatment effect

https://ift.tt/2Ee387e